Recent Company News

• 05:53 AM ET Oct 08, 2026
  

  CSPC Innovation Pharmaceutical discloses phase I clinical trial data of SYS6002 at IGCS 2026 (CNY 45.10, 0.00)

• 10:59 AM ET Oct 06, 2026
  

  StreetAccount Sector Summary - China Healthcare September Recap

• 09:17 PM ET Oct 05, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight +1.71%; Hang Seng Futures (1.66%)

• 07:09 AM ET Oct 05, 2026
  

  CSPC Pharmaceutical Group to present latest updates from 8 clinical trials during ESMO 2026 (HK$9.86, 0.00)

• 09:21 PM ET Sep 30, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight +0.60%; Hang Seng Futures (0.38%)

• 08:14 AM ET Sep 30, 2026
  

  CSPC Pharmaceutical presents results from phase III study of TG103 combined with metformin for type 2 diabetes mellitus in adults at EASD (HK$10.07, 0.00)

• 10:58 PM ET Sep 29, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 09:20 PM ET Sep 29, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight (1.55%); Hang Seng Futures (0.51%)

• 09:23 PM ET Sep 28, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight +1.12%; Hang Seng Futures +0.11%

• 06:18 AM ET Sep 28, 2026
  

  NMPA approves trial of CSPC Pharmaceutical's SYS6077 for advanced malignant tumours (HK$9.39, 0.00)